IRLAB A
14.35
SEK
TODAY
-0.69 %
TODAY SEK
-0.10 SEK
17:00:00
2024-02-23
YEAR LOW
7.6 SEK
YEAR HIGH
18 SEK
ATH:
108.09 SEK
MCAP:
744 MSEK

CEO COMMENTS

Nicholas Waters comments the third quarter 2021

For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB – we have shown that our business model works and that our ISP research platform is an effective tool for developing drug candidates that are attractive to the market.

LATEST REPORTS

Q3

Delårsrapport >

CEO comments >

Presentation >

Q3 Webcast >

Q2

Delårsrapport >

CEO comments >

Presentation >

Q3 Webcast >

2020

Årsrapport >

CEO comments >

Presentation >

2020 Webcast >

LATEST PRESS RELEASE
LATEST PRESENTATION
MAY 25, 2021

IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.

Read More >

FINANCIAL CALENDAR

NEXT

FEBRUARY 23, 2022

Year end report

FOLLOWING

APRIL 4-8, 2022

Annual report

MAY 11, 2022

Annual general meeting